|   |   | 
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/40 | |
| A61P 3/06 | |||
| A61K 39/395 | |||
| A61K 39/00 | 
| (11) | Number of the document | 2756004 | 
| (13) | Kind of document | T | 
| (96) | European patent application number | 12761864.3 | 
| Date of filing the European patent application | 2012-09-12 | |
| (97) | Date of publication of the European application | 2014-07-23 | 
| (45) | Date of publication and mention of the grant of the patent | 2019-12-25 | 
| (46) | Date of publication of the claims translation | 
| (86) | Number | PCT/US2012/054756 | 
| Date | 2012-09-12 | 
| (87) | Number | WO 2013/039969 | 
| Date | 2013-03-21 | 
| (30) | Number | Date | Country code | 
| 201161535392 P | 2011-09-16 | US | |
| 201161559162 P | 2011-11-14 | US | |
| 201261641321 P | 2012-05-02 | US | 
| (72) | 
                    
                    
                    
                    
                    SWERGOLD, Gary, US  | 
| (73) | Regeneron Pharmaceuticals, Inc.,
                777 Old Saw Mill River Road, Tarrytown, NY 10591,
                US | 
| (54) | INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS | 
| INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS |